Unmasking pustular psoriasis subsequent to COVID-19
DOI:
https://doi.org/10.66344/jpad.v31i3.1691Abstract
The various cutaneous manifestations have recently appeared within context of 2019 novel coronavirus diseases (COVID-19). Currently, outbreaks of psoriasis were reported during COVID-19. We reported a case of a 32-year-old woman with COVID-19 who presented with pustular psoriasis. She was treated with oral prednisolone, hydroxyzine and topical clobetasol. The two-week follow-up revealed that her lesions were desquamating and that she was in a favorable situation. The current report will highlight specific skin manifestations of COVID-19, allowing clinicians to further confirm our suspicions.
References
1. Wollina U, Karadağ AS, Rowland‐Payne C, Chiriac A, Lotti T. Cutaneous Signs in COVID‐19 Patients: A Review. Dermatol Ther.2020:e13549.
2. Nasiri S, Araghi F, Tabary M, Gheisari M, Mahboubi-Fooladi Z, Dadkhahfar S. A challenging case of psoriasis flare-up after COVID-19 infection. J Dermatol Treat.2020:1-6.
3. Türsen Ü, Türsen B, Lotti T. Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatol Ther.2020:e13476-e76.
4. Gencler OS, Gencler B, Altunel CT, Arslan N. Levetiracetam induced psoriasiform drug eruption: a rare case report. Saudi Pharm J. 2015;23:720-22.
5. McCoy S, Nagaraja V, Paviol S, Gudjonsson J, Kahlenberg J. Exacerbation of Psoriasis due to Hydroxychloroquine. Arch Med. 2015;7:1-3.
6. Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID‐19: Will cases of psoriasis increase after COVID‐19 pandemic? Dermatol Ther. 2020;e13383.
7. Davoodi L, Jafarpour H, Kazeminejad A, Soleymani E, Akbari Z, Razavi A. Hydroxychloroquine-Induced Stevens-Johnson Syndrome in COVID-19: A rare Case Report. Oxf Med Case Reports.2020;2020:omaa042.
8. Holman AJ. The value of rheumatologists to patients with fibromyalgia: comment on the presidential address by Weinblatt. Arthritis Rheumatism.2002;46:3390.
9. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin.2013;31:405-25.
10. Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol.2019;15:907-19.
11. Rudnicka L, Goldust M, Glowacka P, Sikora M, Sar-Pomian M, Rakowska A, et al. Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern. J Am Acad Dermatol.2020;83:e151-e2.
12. Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis–a model disease for specific targeted immunotherapy, systematic review. Experiment Dermatol.2018;27:1067-77.
13. Choudhary S, McLeod M, Torchia D, Romanelli P. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. J Clin Aesthet Dermatol.2013;6:31-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Zeinab Mohseni Afshar, Ronak Miladi, Alireza Janbakhsh, Arefeh Babazadeh, Zeinab Aryanian, Soheil Ebrahimpour
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
